Zubor Pavol, Kajo Karol, Stanclova Andrea, Szunyogh Norbert, Galo Silvester, Dussan Carlos A, Minarik Gabriel, Visnovsky Jozef, Danko Jan
Department of Obstetrics and Gynecology, Comenius University, Bratislava, Slovak Republic.
Eur J Cancer Prev. 2008 Feb;17(1):33-8. doi: 10.1097/CEJ.0b013e3280145e4b.
Studies on the association between the Ile to Val polymorphism at codon 655 of the human epithelial growth factor receptor 2 (HER-2) gene and susceptibility to breast cancer have been reported for almost all ethnic populations, with both positive or negative conclusions. No study, however, has yet been focused on the possible association between this gene and its predisposition to benign breast lesions, especially on risk for fibroadenoma. We aimed to study the association of the single nucleotide polymorphism V655 HER-2 gene polymorphism with histologically verified breast fibroadenoma risk. We conducted a molecular epidemiological case-control study of 70 breast fibroadenoma cases without cellular atypia and 172 healthy female controls. We found that the Val variant allele and genotype frequency of this polymorphism is higher in cases with fibroadenoma; however, this difference was not significant (allele Val 655: 27.86 and 22.67% in fibroadenoma and controls, respectively; genotype Ile/Val: 35.71 and 38.37% and Val/Val: 10.0 and 3.49% in fibroadenoma and controls, respectively). Applying logistic regression analysis, we found an increased risk of fibroadenoma formation in carriers of the Val allele (odds ratio = 1.17; 95% confidence interval = 0.67-2.05), in which the highest risk was associated with homozygous genotype (odds ratio = 3.07; 95% confidence interval = 0.97-9.72), but this risk was not significant. Stratification by age (cut-off 45 years) revealed the highest risk of fibroadenoma among young women homozygous for the Val allele (odds ratio = 3.30). The risk, however, was slightly increased (odds ratio = 1.24) among older carriers of the aberrant allele in their genotype as well, but it was not significant. In spite of insignificant differences, our results indicate that HER-2 Ile655Val polymorphism, especially in a homozygous form might play some role in the etiology of breast fibroadenoma formation. The significance of this susceptibility, however, will have to be verified by larger studies.
关于人类表皮生长因子受体2(HER-2)基因第655密码子异亮氨酸至缬氨酸多态性与乳腺癌易感性之间的关联研究,几乎在所有种族人群中均有报道,结论有正有负。然而,尚无研究聚焦于该基因与良性乳腺病变易感性之间的可能关联,尤其是与纤维腺瘤风险的关联。我们旨在研究单核苷酸多态性V655 HER-2基因多态性与经组织学证实的乳腺纤维腺瘤风险之间的关联。我们对70例无细胞异型性的乳腺纤维腺瘤病例和172名健康女性对照进行了分子流行病学病例对照研究。我们发现,该多态性的缬氨酸变异等位基因和基因型频率在纤维腺瘤病例中更高;然而,这种差异并不显著(等位基因Val 655:纤维腺瘤组和对照组分别为27.86%和22.67%;基因型Ile/Val:纤维腺瘤组和对照组分别为35.71%和38.37%,Val/Val:纤维腺瘤组和对照组分别为10.0%和3.49%)。应用逻辑回归分析,我们发现缬氨酸等位基因携带者发生纤维腺瘤的风险增加(比值比=1.17;95%置信区间=0.67 - 2.05),其中风险最高的是纯合基因型(比值比=3.07;95%置信区间=0.97 - 9.72),但该风险并不显著。按年龄分层(以45岁为界)显示,缬氨酸等位基因纯合的年轻女性患纤维腺瘤的风险最高(比值比=3.30)。然而,在年龄较大的该异常等位基因基因型携带者中,风险也略有增加(比值比=1.24),但不显著。尽管差异不显著,但我们的结果表明,HER-2 Ile655Val多态性,尤其是纯合形式,可能在乳腺纤维腺瘤形成的病因中起一定作用。然而,这种易感性的意义仍需通过更大规模的研究来验证。